Sharyn Baker

Image
Sharyn Baker

Sharyn Baker, PharmD, PhD

Title
Gertrude Parker Heer Chair in Cancer Research,
Secondary Title
Professor and Chair
Unit / Department / Division
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences Affiliated Faculty
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations. Dr. Baker’s research interests include developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anti-cancer drug disposition and investigational anti-cancer drug development.

Education

  • 2004, Ph.D., Erasmus University Rotterdam, Medicine
  • 1991, Pharm.D., University of California, San Francisco, Pharmacy
  • 1986, B.A., Pacific Lutheran University, Biology
  • California State Board of Pharmacy No. 40219 (inac, California State Board of Pharmacy

Honors

  • Clinical and Translational Science Award, 2017

Journal Articles

  • Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng MJHH, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS. A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nat Commun. 2020 Apr 21;11(1):1924.
  • Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metab Dispos. 2020 May;48(5):419-425.
  • Elgamal OA, Mehmood A, Jeon JY, Carmichael B, Lehman A, Orwick SJ, Truxall J, Goettl VM, Wasmuth R, Tran M, Mitchell S, Lapalombella R, Eathiraj S, Schwartz B, Stegmaier K, Baker SD, Hertlein E, Byrd JC. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. J Hematol Oncol. 2020 Jan 28;13(1):8.
  • Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics. 2020 Sep 9;12(9):856.
  • Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics. 2020 Aug 20;12(9):788.
  • Baker SD, Mosley M, Roche C. Seven Specific Diseases: Increasing Engagement With a Collaborative Interactive Approach. J Nurs Educ. 2020 Jul 1;59(7):419.
  • Díaz SR, Baker SD, Medio FJ. Helping Students Navigate the Single Graduate Medical Education Accreditation System. J Am Osteopath Assoc. 2020 Apr 1;120(4):216.
  • Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD. TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI Insight. 2020 Dec 3;5(23):e140169.
  • Sheridan DC, Dehart R, Lin A, Sabbaj M, Baker SD. Heart Rate Variability Analysis: How Much Artifact Can We Remove? Psychiatry Investig. 2020 Sep;17(9):960-965.
  • Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clin Pharmacol Ther. 2020 Jan;107(1):227-237.
  • Choi NG, Marti CN, DiNitto DM, Baker SD. Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019. Clin Toxicol (Phila). 2020 Aug 25:1-9.
  • Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2020 Sep 9.
  • Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD. Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122176.
  • Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs. 2020 Apr;38(2):340-349.
  • Anderson, J.T.; Hu, S.; Fu, Q.; Baker, S.D. et al. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice Pharmacology Research and Perspectives. 2019 Dec; 7(6):.